Dublin, Ireland, June 22, 2015 – Inflection Biosciences Ltd, a private company developing highly innovative treatments for cancer, today announced that its Director of Research and Development, Dr Michael O’Neill, was interviewed by Pharma Television’s Fintan Walton about its promising kinase inhibitor programs which are in development for cancer. To watch the interview, please follow the link here.
About Inflection Biosciences
Inflection Biosciences Ltd, based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises IBL-202 (PIM/PI3K inhibitor) and IBL-301 (PIM/PI3K/mTOR inhibitor), selected from a series of unique dual mechanism kinase inhibitors and the IBL-100 series (highly selective pan-PIM kinase inhibitors), currently in pre-clinical stages of development. Data generated to date suggests potential application in a range of haematological malignancies and treatment resistant solid tumours. Inflection Biosciences was named ‘Start-up Company of the Year’ at the 2014 Irish Pharma Awards. For more information please visit www.inflectionbio.com
Commentaires